INCB-100658
- Generic Name
- INCB-100658
JAK Inhibitors Pipeline Expands with 55+ Drug Candidates as Major Pharma Companies Drive Innovation
• The JAK inhibitors therapeutic landscape shows robust growth with over 50 pharmaceutical companies developing 55+ pipeline candidates across various clinical stages.
• Key drug candidates including Povorcitinib, Zasocitinib, and Ritlecitinib are advancing through late-stage clinical trials for conditions like vitiligo, psoriasis, and ulcerative colitis.
• Recent developments include promising results from Pelabresib-ruxolitinib combination therapy for myelofibrosis and expanded access initiatives by Eli Lilly for baricitinib in Africa.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath